Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Abstract EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ong...

Full description

Bibliographic Details
Main Authors: Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč, Kārlis Trušinskis
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
CVOTs
Real-world evidence
EMPRISE
EMPA-REG OUTCOME
Heart failure
Online Access:http://link.springer.com/article/10.1186/s12933-019-0920-3

Internet

http://link.springer.com/article/10.1186/s12933-019-0920-3

Similar Items